CY1109766T1 - Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv - Google Patents

Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv

Info

Publication number
CY1109766T1
CY1109766T1 CY20101100099T CY101100099T CY1109766T1 CY 1109766 T1 CY1109766 T1 CY 1109766T1 CY 20101100099 T CY20101100099 T CY 20101100099T CY 101100099 T CY101100099 T CY 101100099T CY 1109766 T1 CY1109766 T1 CY 1109766T1
Authority
CY
Cyprus
Prior art keywords
protease inhibitors
hiv protease
azapeptide derivatives
azapeptide
derivatives
Prior art date
Application number
CY20101100099T
Other languages
Greek (el)
English (en)
Inventor
Scott L Harbeson
Roger D Tung
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of CY1109766T1 publication Critical patent/CY1109766T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CY20101100099T 2007-06-12 2010-02-03 Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv CY1109766T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
EP08252023A EP2003120B9 (en) 2007-06-12 2008-06-12 Azapeptide derivatives as HIV protease inhibitors

Publications (1)

Publication Number Publication Date
CY1109766T1 true CY1109766T1 (el) 2014-09-10

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100099T CY1109766T1 (el) 2007-06-12 2010-02-03 Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv

Country Status (25)

Country Link
US (4) US20090036357A1 (show.php)
EP (3) EP2116532B1 (show.php)
JP (1) JP2010529196A (show.php)
KR (2) KR101185899B1 (show.php)
CN (2) CN102424668A (show.php)
AR (1) AR066972A1 (show.php)
AT (2) ATE447554T1 (show.php)
AU (1) AU2008267048C1 (show.php)
BR (2) BRPI0823520A2 (show.php)
CA (1) CA2692028C (show.php)
CO (1) CO6241121A2 (show.php)
CY (1) CY1109766T1 (show.php)
DE (1) DE602008000255D1 (show.php)
DK (1) DK2003120T3 (show.php)
ES (3) ES2394952T3 (show.php)
HR (1) HRP20100065T1 (show.php)
MX (1) MX2009013565A (show.php)
PL (1) PL2003120T3 (show.php)
PT (1) PT2003120E (show.php)
RS (1) RS51226B (show.php)
RU (2) RU2448958C2 (show.php)
SI (1) SI2003120T1 (show.php)
TW (1) TW200908970A (show.php)
WO (1) WO2008156632A1 (show.php)
ZA (1) ZA200909079B (show.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103899A1 (en) * 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
PL2003120T3 (pl) 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
US9163067B2 (en) * 2008-10-06 2015-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
US8784858B2 (en) 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
ME02513B (me) 2011-06-20 2017-02-20 H Lundbeck As Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
KR102774942B1 (ko) * 2015-12-02 2025-02-27 머크 샤프 앤드 돔 엘엘씨 도라비린, 테노포비르 디소프록실 푸마레이트 및 라미부딘을 함유하는 제약 조성물
EP3436461B1 (en) 2016-03-28 2023-11-01 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
MY208007A (en) 2017-09-27 2025-04-04 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021212022A1 (en) * 2020-04-16 2021-10-21 The Medical College Of Wisconsin, Inc. Aerosolized formulations of hiv protease inhibitors for the treatment of airway reflux
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK224286A (da) 1985-05-15 1986-11-16 Wellcome Found 2',3'-dideoxy-nucleosider
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
EP1090914B1 (en) 1992-12-29 2003-01-02 Abbott Laboratories Retroviral protease inhibiting compounds
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
JP2005501880A (ja) 2001-08-31 2005-01-20 ブリストル−マイヤーズ スクイブ カンパニー Hiv療法におけるアタザナビルの使用
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2004273773B2 (en) 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
EP2336138A3 (en) * 2004-07-06 2011-11-16 Abbott Laboratories Prodrugs of HIV protease inhibitors
CA2581169A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
MX2007006637A (es) 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
PL2003120T3 (pl) * 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
ATE536343T1 (de) 2011-12-15
RU2012101881A (ru) 2013-07-27
JP2010529196A (ja) 2010-08-26
PL2003120T3 (pl) 2010-04-30
CN101711237B (zh) 2013-08-07
US8258309B2 (en) 2012-09-04
TW200908970A (en) 2009-03-01
ZA200909079B (en) 2011-05-25
BRPI0823520A2 (pt) 2013-12-17
WO2008156632A1 (en) 2008-12-24
SI2003120T1 (sl) 2010-03-31
EP2116532A1 (en) 2009-11-11
ES2394952T3 (es) 2013-02-07
EP2003120B1 (en) 2009-11-04
CN102424668A (zh) 2012-04-25
AU2008267048B2 (en) 2012-05-31
CO6241121A2 (es) 2011-01-20
EP2322509B1 (en) 2012-08-22
ATE447554T1 (de) 2009-11-15
US8158805B2 (en) 2012-04-17
AU2008267048A1 (en) 2008-12-24
US20130041156A1 (en) 2013-02-14
KR20120029480A (ko) 2012-03-26
US20110009355A1 (en) 2011-01-13
ES2395137T3 (es) 2013-02-08
CN101711237A (zh) 2010-05-19
DK2003120T3 (da) 2010-03-15
EP2322509A1 (en) 2011-05-18
EP2003120A1 (en) 2008-12-17
CA2692028C (en) 2013-06-04
CA2692028A1 (en) 2008-12-24
RU2010100821A (ru) 2011-07-20
US20090036357A1 (en) 2009-02-05
HK1136576A1 (en) 2010-07-02
RU2448958C2 (ru) 2012-04-27
HK1127345A1 (en) 2009-09-25
MX2009013565A (es) 2010-06-02
EP2116532B1 (en) 2011-12-07
AU2008267048C1 (en) 2013-01-17
RS51226B (sr) 2010-12-31
AR066972A1 (es) 2009-09-23
DE602008000255D1 (de) 2009-12-17
BRPI0813911A2 (pt) 2012-02-22
HRP20100065T1 (hr) 2010-03-31
EP2003120B9 (en) 2010-06-02
KR101185899B1 (ko) 2012-09-27
US20120165288A1 (en) 2012-06-28
ES2356334T3 (es) 2011-04-07
PT2003120E (pt) 2010-02-11
KR20100020033A (ko) 2010-02-19

Similar Documents

Publication Publication Date Title
CY1109766T1 (el) Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv
CY1112221T1 (el) S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv
CY1121265T1 (el) Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CR20130369A (es) Novedosos derivados heterocíclicos
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
ATE552255T1 (de) 4-aminoindazole
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
CR20130537A (es) Compuestos heterocíclicos como inhibidores de cinasas
CY1113727T1 (el) Παραγωγα πυριδιν-4-υλ ως ανοσορυθμιστικοι παραγοντες
CR20120417A (es) Inhibidores de virus flaviviridae
BR112015004111A2 (pt) novos derivados bicíclicos
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
CR10662A (es) Compuestos de metilpiridopirimidinona
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
ATE542798T1 (de) Organische verbindungen
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
EA201101026A1 (ru) Ингибиторы бета-секретазы
MA32142B1 (fr) Forme cristalline de dérivés de phénylamino pyrimidine
EA200900946A1 (ru) Новый способ синтеза агомелатина
HRP20080554A2 (hr) Postupak priprave inhibitora proteaze hiv